Physician profile
Nicholas Uffelmann
NPI 1912261934
$559.43
in general payments reported to CMS, 2019-2025
13 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $12.72 · 2022: $12.86 · 2024: $129 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $141.94 | 2025 | Tremfya |
| Abbvie INC. | $131.52 | 2019-2025 | |
| Pfizer INC. | $69.90 | 2019 | |
| Amgen INC. | $51.94 | 2024 | Otezla |
| Lilly USA, LLC | $28.28 | 2025 | Zepbound, Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $25.58 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.00 | 2019 | |
| Genzyme Corporation | $19.77 | 2025 | |
| Arcutis Biotherapeutics, INC. | $17.22 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $16.69 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $16.38 | 2024 | |
| Integra Lifesciences Corporation | $13.76 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Organon LLC | $2.45 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Uffelmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.